Despite high specificity, the tests show low sensitivity for early-stage cancers, necessitating further validation through ...

Minimal residual disease-negativity after treatment in DLBCL strongly correlates with remission and overall survival. However ...

Multicancer early detection tests are revolutionizing cancer screening by using liquid biopsies to screen for multiple ...

DNA methylation, RTK pathway changes, and KRAS amplifications may drive resistance to sotorasib plus panitumumab in KRAS G12C ...

The smartphone-sized, battery-powered test is a cost-effective tool that can improve TB diagnoses, particularly in rural areas where facilities and equipment are less accessible. Dr. Tony Hu, a Tulane ...

Company continues to progress both REYOBIQ radiotherapeutic clinical trials and CNSide® CSF assay platform launch readiness HOUSTON, May 30, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: ...

Company continues to progress both REYOBIQTM radiotherapeutic clinical trials and CNSide® CSF assay platform launch readiness HOUSTON, May ...

The investigators undertook a retrospective analysis of patients with advanced urothelial carcinoma who were longitudinally tested for ctDNA (MTM/mL) with a tumor-informed assay while on treatment ...

Scientists at the Liverpool School of Tropical Medicine (LSTM) have developed a more precise diagnostic tool to distinguish ...

Oncology specialists from UC San Francisco will present new clinical research findings and cutting-edge treatment strategies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that ten abstracts have been accepted for presentation at ...

EpiCypher, a leader in epigenomic technologies, has introduced two innovative DNA methylation sequencing assays - CUTANA® meCUT&RUN and Multiomic CUT&RUN - that offer scalable, high-resolution ...